Stanford Medicine researchers say artificial intelligence helped them identify a naturally occurring molecule called BRP that may suppress appetite and lower body weight. Based on the report, BRP appears to work in a way that resembles semaglutide, the active ingredient in Ozempic, one of the best-known weight-loss and diabetes drugs.
What makes the Stanford finding notable is the suggestion that BRP may avoid several of the side effects often linked to current treatments. The researchers describe the molecule as acting on a more targeted region of the brain, which could make its effects more precise while still influencing hunger and weight.
The study is drawing attention because many patients and doctors are interested in treatments that can deliver appetite control without the drawbacks that sometimes come with existing medications. A naturally occurring molecule with Ozempic-like benefits would be a significant development if further research confirms the early results.
The report also highlights how AI is being used to speed up biomedical discovery. In this case, the technology helped Stanford scientists uncover a promising compound already found in nature, pointing to a new direction for future obesity and appetite research.
